Sustained delivery of a heterodimer bone morphogenetic protein-2/7 via a collagen hydroxyapatite scaffold accelerates and improves critical femoral defect healing
Acta Biomaterialia · 2023-05 · 162 · 164-181
DOI: 10.1016/j.actbio.2023.03.028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2023-05. Verfasst von Yang Liu und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Faculty of Medicine, Department of Clinical Sciences Lund, Orthopedics, Lund University, BMC C12, Klinikgatan 28, Lund 221 84, Sweden. Hauptthemen laut MEDLINE: Durapatite, Bone Substitutes. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Crafoordska Stiftelsen, Lunds Universitet, Sten K Johnsons stiftelse.
Abstract (Originalsprache)
Despite the glimmer of hope provided by the discovery and commercialization of bone morphogenetic protein-2 (BMP-2) as a bone graft substitute, side effects related to the use of supraphysiological doses have hindered its clinical usage. In this study, we compared the osteoinductive potential of BMP-2 homodimer with a heterodimer of BMP-2/7, both delivered via a collagen-hydroxyapatite (CHA) scaffold delivery system, with the aim to reduce the overall therapeutic BMP doses and the associated side-effects. We first show that the incorporation of hydroxyapatite in collagen-based BMP delivery systems is pivotal for achieving efficient BMP sequestration and controlled release. Using an ectopic implantation model, we then showed that the CHA+BMP-2/7 was more osteoinductive than CHA+BMP-2. Further evaluation of the molecular mechanisms responsible for this increased osteoinductivity at an early stage in the regeneration process indicated that the CHA+BMP-2/7 enhanced progenitor cell homing at the implantation site, upregulated the key transcriptomic determinants of bone formation, and increased the production of bone extracellular matrix components. Using fluorescently labelled BMP-2/7 and BMP-2, we demonstrated that the CHA scaffold provided a long-term delivery of both molecules for at least 20 days. Finally, using a rat femoral defect model, we showed that an ultra-low dose (0.5 µg) of BMP-2/7 accelerated fracture healing and performed at a level comparable to 20-times higher BMP-2 dose. Our results indicate that the sustained delivery of BMP-2/7 via a CHA scaffold could bring us a step closer in the quest for the use of physiological growth factor doses in fracture healing. STATEMENT OF SIGNIFICANCE: • Incorporation of hydroxyapatite (HA) in a collagen scaffold dramatically improves bone morphogenic protein (BMP) sequestration via biophysical interactions with BMP, thereby providing more controlled BMP release compared with pristine collagen. • We then investigate the molecular mechanisms responsible for increased osteoinductive potential of a heterodimer BMP-2/7 with is clinically used counterpart, the BMP-2 homodimer. • The superior osteoinductive properties of BMP-2/7 are a consequence of its direct positive effect on progenitor cell homing at the implantation site, which consequently leads to upregulation of cartilage and bone related genes and biochemical markers. • An ultra-low dose of BMP-2/7 delivered via a collagen-HA (CHA) scaffold leads to accelerated healing of a critical femoral defect in rats while a 20-times higher BMP-2 dose was required to achieve comparable results.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Faculty of Medicine, Department of Clinical Sciences Lund, Orthopedics, Lund University, BMC C12, Klinikgatan 28, Lund 221 84, Sweden.
- The Faculty of Medicine, Division of Dermatology and Venerology, Lund University, Lund 221 84, Sweden.
- Tissue Engineering Research Group, Department of Anatomy and Regenerative Medicine, Royal College of Surgeons in Ireland, University of Medicine and Health Sciences, 123 St. Stephens Green, Dublin, Ireland; Advanced Mat…
- The Faculty of Medicine, Department of Laboratory Medicine, Division of Microbiology, Immunology and Glycobiology, Lund University, Lund 221 84, Sweden.
- Department of Clinical Sciences Lund, Stem Cell Centre, Cell, Tissue & Organ Engineering Laboratory, Lund University, BMC B11, Lund 221 84, Sweden; Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.
- Trauma and Plastic Surgery, University Hospital Carl Gustav Carus at Technische Universität Dresden, University Center of Orthopedics, Dresden 01307, Germany.
Förderung
- Crafoordska Stiftelsen
- Lunds Universitet
- Sten K Johnsons stiftelse
- European Research Council
- Health Research Board
Zitieren
APA
Liu, Y., Puthia, M., Sheehy, E. J., Ambite, I., Petrlova, J., Prithviraj, S., Oxborg, M. W., Sebastian, S., Vater, C., Zwingenberger, S., Struglics, A., Bourgine, P. E., O'Brien, F. J., & Raina, D. B. (2023). Sustained delivery of a heterodimer bone morphogenetic protein-2/7 via a collagen hydroxyapatite scaffold accelerates and improves critical femoral defect healing. Acta Biomaterialia, 162, 164-181. https://doi.org/10.1016/j.actbio.2023.03.028
Vancouver
Liu Y, Puthia M, Sheehy EJ, Ambite I, Petrlova J, Prithviraj S, et al. Sustained delivery of a heterodimer bone morphogenetic protein-2/7 via a collagen hydroxyapatite scaffold accelerates and improves critical femoral defect healing. Acta Biomaterialia. 2023;162:164-181. doi:10.1016/j.actbio.2023.03.028
BibTeX
@article{Liu2023,
author = {Liu, Yang and Puthia, Manoj and Sheehy, Eamon J and Ambite, Ines and Petrlova, Jitka and Prithviraj, Sujeethkumar and Oxborg, Maria Wimer and Sebastian, Sujeesh and Vater, Corina and Zwingenberger, Stefan and Struglics, André and Bourgine, Paul E and O'Brien, Fergal J and Raina, Deepak Bushan},
title = {Sustained delivery of a heterodimer bone morphogenetic protein-2/7 via a collagen hydroxyapatite scaffold accelerates and improves critical femoral defect healing},
journal = {Acta Biomaterialia},
year = {2023},
volume = {162},
pages = {164--181},
doi = {10.1016/j.actbio.2023.03.028}
}
EUVIMED